Stoke Therapeutics, Inc. 8-K

What Happened
Stoke Therapeutics announced in an 8‑K that on March 23, 2026 the Audit Committee dismissed KPMG LLP as the company’s independent registered public accounting firm and approved Ernst & Young LLP (EY) as the new independent auditor for the fiscal year ending December 31, 2026. KPMG’s audit reports for the years ended December 31, 2025 and 2024 were unmodified (no adverse or disclaimer opinions), and the company states there were no disagreements or “reportable events” with KPMG during those years or through March 23, 2026. The company filed KPMG’s letter dated March 27, 2026 as an exhibit to the 8‑K.

Key Details

• Dismissal and appointment both approved by the Audit Committee on March 23, 2026.
• KPMG’s reports for fiscal years ended December 31, 2025 and 2024 were unmodified and contained no qualifications.
• No disagreements or reportable events occurred between the company and KPMG for the periods noted.
• The company did not consult EY on the matters covered by SEC Item 304 during the two most recent fiscal years or the interim through March 23, 2026.

Why It Matters
A change in independent auditor is a governance event investors watch because the auditor provides assurance over financial statements. Here, the filing shows no prior audit disagreements or reportable events and unmodified opinions from KPMG, which suggests there were no unresolved accounting issues at the time of the change. Investors should note EY will audit the company for fiscal 2026; any future audit opinions, disclosures about audit fees or accounting adjustments will be important for assessing financial reporting and controls.